Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant in Obese Patients With Type 2 Diabetes
NCT00029848Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2001
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of rimonabant in obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoint: Change in Body Weight at 1 year. Started Oct 2001; status: completed.
02
Drugs
rimonabant
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00029848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00029848.